The Technical Analyst
Sight Sciences, Inc. [SGHT]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Medical Devices
Sight Sciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.27% $7.46
America/New_York / 6 jun 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 361.51 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 13, 2023 |
| SharesOutstanding: | 48.46 mill |
| Avg Daily Volume: | 0.114 mill |
| RATING 2023-06-06 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE 0 | industry: PE 229.20 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$11.33 (51.83%) $3.87 |
| Date: 2023-06-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.68 - 8.24 ( +/- 10.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-09 | Bauerlein Alison | Buy | 103 000 | Common Stock |
| 2023-05-09 | Bauerlein Alison | Buy | 71 800 | Stock Option (Right to Buy) |
| 2023-04-03 | Bauerlein Alison | Buy | 0 | |
| 2023-03-16 | Hayden Jeremy B. | Buy | 45 100 | Common Stock |
| 2023-03-16 | Hayden Jeremy B. | Buy | 57 700 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 6.16 |
| Last 95 transactions |
| Buy: 26 749 307 | Sell: 23 909 759 |
Forecast:
16:00 - $7.46
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.46
Forecast 2: 16:00 - $7.46
Forecast 3: 16:00 - $7.46
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.46 (-0.27% ) |
| Volume | 0.123 mill |
| Avg. Vol. | 0.114 mill |
| % of Avg. Vol | 107.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SGHT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Last 10 Buy Signals
Latest Press Releases
2023-05-23 08:30:00 - Press Release
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions In Both Intraocular Pressure (iop) And Glaucoma Medication Use In Mild-moderate Primary Open Angle Glaucoma Patients Treated With A Procedure Enabled With The Omni® Surgical System Technology
Retrospective clinical data from seven us sites published in clinical ophthalmology sustained and clinically meaningful iop reductions observed at 12 months persisted through 24 months sustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted through 24 months confirmed safety and efficacy of omni surgical system technology in both standalone and combination cataract procedures longest published multicenter clinical results of omni surgical system to date menlo park, calif., may 23, 2023 (globe newswire) -- sight sciences, inc. (nasdaq: sght), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the publication of two-year results of the romeo (retrospective, observational, multicenter, evaluation of omni) study in clinical ophthalmology.
2023-05-06 11:30:00 - Press Release
Sight Sciences Announces 12-month Results From The First Minimally Invasive Glaucoma Surgery (migs) Comparative Analysis Of Real-world Data (rwd) From The American Academy Of Ophthalmology Iris® Registry
Patients undergoing procedures enabled with omni® surgical system technology experienced a greater average reduction in iop-lowering medication usage compared to other migs procedures or cataract surgery alone patients undergoing procedures enabled with omni® surgical system technology experienced a greater average reduction in iop-lowering medication usage compared to other migs procedures or cataract surgery alone
2023-04-13 16:05:00 - Press Release
Sight Sciences To Host Surgical Glaucoma Investor Symposium On Friday, May 5, 2023
The event will include presentations from leading glaucoma surgeons and remarks from the sight sciences executive management team the event will include presentations from leading glaucoma surgeons and remarks from the sight sciences executive management team
2023-04-03 16:05:00 - Press Release
Sight Sciences Appoints Ali Bauerlein As Chief Financial Officer
Menlo park, calif., april 03, 2023 (globe newswire) -- sight sciences, inc. (nasdaq: sght) (“sight sciences” or the “company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of alison “ali” bauerlein as its chief financial officer and treasurer, effective april 3, 2023.
2023-03-30 08:00:00 - Press Release
Sight Sciences Defeats Invalidity Challenges Filed By Alcon And Ivantis In The U.s. Patent Office
Menlo park, calif., march 30, 2023 (globe newswire) -- sight sciences, inc. (nasdaq: sght) (“sight sciences,” or the “company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today reported that it defeated all four patent invalidity challenges filed by alcon and ivantis in the united states patent and trademark office.
Latest News
2023-05-30 17:00:54 - Seeking Alpha
Sight Sciences: Recent Stock Price Pullback Is Unwarranted
Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 metrics offered positive read-throughs for the company's growth prospects. I continue to rate Sight Sciences, Inc. stock as a Buy, as I view Sight's recent share price weakness and valuation discount to peers as unjustified.
2023-05-09 11:28:11 - Zacks Investment Research
How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%
The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-05-07 07:58:17 - Seeking Alpha
Sight Sciences, Inc. (SGHT) Q1 2023 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Phillip Dantoin - Piper Sandler Thomas Stephan - Stifel Michael Arens - William Blair Operator Good day and thank you for standing by. Welcome to the Sight Sciences First Quarter 2023 Earnings Results Call.
2023-05-04 20:30:51 - Zacks Investment Research
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.49 per share a year ago.
2023-04-26 16:05:00 - GlobeNewsWire
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Bank of America Securities 2023 Health Care Conference in Las Vegas, NV.
2023-04-20 16:05:00 - GlobeNewsWire
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 4, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-04-11 06:52:06 - Zacks Investment Research
Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?
Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-03-13 22:23:06 - Seeking Alpha
Sight Sciences, Inc. (SGHT) Q4 2022 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jim Rodberg - Interim Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Thomas Stephan - Stifel Financial Corp. Craig Bijou - Bank of America Securities, Inc. Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Margaret Kaczor - William Blair Matthew O'Brien - Piper Sandler David Saxon - Needham & Company Operator Hello, and welcome to Sight Sciences Fourth Quarter 2022 Earnings Results. At this time, all participants are in listen-only mode.
2023-03-13 19:07:55 - Zacks Investment Research
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-02-23 16:05:00 - GlobeNewsWire
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Monday, March 13, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.